Economic evaluations conducted for assessment of genetic testing technologies: A systematic review

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 11, 2012, Pages 1322-1335

  Assasi, Nazila ^a   Schwartz, Lisa ^a,b   Tarride, Jean Eric ^a,b   Goeree, Ron ^a   Xie, Feng ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DEVICE SAFETY; ECONOMIC EVALUATION; GENETIC SCREENING; HEALTH TECHNOLOGY ASSESSMENT; INFORMATION RETRIEVAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW (TOPIC);

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; GENETIC TESTING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; RESEARCH DESIGN; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84868034874     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0178     Document Type: Review

References (36)

1. Agency for Healthcare Research and Quality (2007) Cost-effectiveness of DNA stool testing to screen for colorectal cancer (Brief record). Rockville: Agency for Healthcare Research and Quality (AHRQ) Available at www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads//id52TA.pdf (accessed May 3 2012).
2. Armengol L, Nevado J, Serra-Juhe C, et al. (2012) Clinical utility of chromosomal microarray analysis in invasive prenatal diagnosis. Hum Genet 131:513-523.
3. Beech R, Rona RJ, Mandalia S (1994) The resource implications and service outcomes of genetic services in the context of DNA technology. Health Policy 26:171-190. (Pubitemid 24087604)
4. Botkin JR, Teutsch SM, Kaye CI, et al. (2010) Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med 12:228-235.
5. Briggs AH, Gray AM (1999) Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319:635-638. (Pubitemid 29414568)
6. Bryant J, Cooper K, Picot J, et al. (2009) Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation. Health Technology Assessment 13 (23) Available at www.hta .ac.uk/fullmono/mon1323.pdf (accessed May 3 2012).
7. Byford S, Raftery J (1998) Perspectives in economic evaluation. BMJ 316:1529-1530.
8. Carlson JJ, Henrikson NB, Veenstra DL, et al. (2005) Economic analyses of human genetics services: a systematic review. Genet Med 7:519-523. (Pubitemid 41566478)
9. Dinh TA, Rosner BI, Atwood JC, et al. (2011) Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 4:9-22.
10. Djalalov S, Musa Z, Mendelson M, et al. (2011) A review of economic evaluations of genetic testing services and interventions (2004-2009). Genet Med 13:89-94.
11. Drummond MF, Sculpher MJ, Torrance GW, et al. (2005) Methods for the Economic Evaluation of Health Care Programmes. Third ed. Oxford University Press Inc., New York.
12. European Network for Health Technology Assessment (2012) Definition of HTA. Available at www.eunethta.eu/Public/About-EUnetHTA/HTA/(accessed May 3 2012).
13. Grimshaw GM, Szczepura A, Hulten M, et al. (2003) Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities. Health Technol Assess 7:1-146.
14. Grosse SD, Wordsworth S, Payne K (2008) Economic methods for valuing the outcomes of genetic testing: beyond costeffectiveness analysis. Genet Med 10:648-654.
15. Hoch JS, Smith MW (2006) A guide to economic evaluation: methods for cost-effectiveness analysis of person-level data. J Trauma Stress 19:787-797. (Pubitemid 46424355)
16. Jonsson B (2009) Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 10:357-359.
17. Karnon J, Goyder E, Tappenden P, et al. (2007) A review and critique of modelling in prioritising and designing screening programmes. Health Technol Assess 11:iii-xi, 1.
18. Lee DW, Neumann PJ, Rizzo JA (2010) Understanding the medical and nonmedical value of diagnostic testing. Value Health 13:310-314.
19. Lesko LJ, Woodcock J (2004) Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 3:763-769. (Pubitemid 39242828)
20. Marks D, Wonderling D, Thorogood M, et al. (2000) Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. [Review] [134 refs]. Health Technol Assess 4:1-123.
21. Medical Advisory Secretariat (2010a) Epidermal growth factor receptor (EGFR) genetic testing for prediction of response to EGFR-targeted (TKI) drugs in patients with advanced nonsmall-cell cancer: an evidence-based analysis. Ont Health Technol Assess Ser [internet] 10:1-48.
22. Medical Advisory Secretariat (2010b) Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser [internet] 10:1-57.
23. Medical Advisory Secretariat (2010c) KRAS testing for anti-EGFR therapy in advanced colorectal cancer: an evidencebased and economic analysis. Ont Health Technol Assess Ser [internet] 10:1-49.
24. Medical Services Advisory Committee (2002) Genetic test for fragile X syndrome (Structured abstract). Canberra: Medical Services Advisory Committee (MSAC):52. Available at www.msac.gov.au/internet/msac/publishing.nsf/Content/ 1E0803AD53E44E39CA2575AD0082FD91/$File/1035%20- %20Genetic%20test%20for%20fragile%20X%20syndrome% 20Report.pdf (accessed May 3 2012).
25. Murray J, Cuckle H, Taylor G, et al. (1997) Screening for fragile X syndrome. Health Technol Assess 1:i-iv, 1-71.
26. Ofman JJ, Sullivan SD, Neumann PJ, et al. (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 9:53-61.
27. Phillips KA, Veenstra DL, Ramsey SD, et al. (2004) Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care 10 (7 Pt 1):425-432. (Pubitemid 38970239)
28. Robinson R (1993) Cost-benefit analysis. BMJ 307:924-926. (Pubitemid 23293512)
29. Rogowski W (2006) Genetic screening by DNA technology: a systematic review of health economic evidence. [Review] [51 refs]. Int J Technol Assess Health Care 22:327-337. (Pubitemid 44469439)
30. Rogowski W (2007) Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 80:340-357. (Pubitemid 44914099)
31. Rogowski WH, Grosse SD, Khoury MJ (2009) Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 10:489-495.
32. Sharma P, Boyers D, Boachie C, et al. (2012) Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess 16:1-266.
33. Song FJ, Barton P, Sleightholme V, et al. (2003) Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 7:1-106.
34. Szczepura A, Westmoreland D, Vinogradova Y, et al. (2006) Evaluation of molecular techniques in prediction and diagnosis of cytomegalovirus disease in immunocompromised patients. Health Technol Assess 10:1-176.
35. The National Center for Biotechnology Information (2011) Educational materials: uses of enetic testing. Genetests: medical genetics information resource [internet]. University of Washington, Seatle Available at www.genetests.org (accessed May 2 2012).
36. Wong WB, Carlson JJ, Thariani R, et al. (2010) Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 28:1001-1013.